763E Concord Avenue
14 articles with Cyteir Therapeutics
6/23/2021Life sciences advances continue to be an exciting opportunity for investors. Here's a glance at the companies attracting fresh funding the past week.
Cyteir Therapeutics, Inc. today announced the closing of its initial public offering of 7,400,000 shares of its common stock at an initial public offering price of $18.00 per share.
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), today announced the pricing of its initial public offering of 7,400,000 shares of its common stock at an initial public offering price of $18.00 per share
The last few weeks have seen a flurry of filings for initial public offerings by biotech companies. Here’s a look.
Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials of Lead RAD51 Program
Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies for cancer, today announced the close of an oversubscribed $80 million Series C financing.
Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies to treat cancer, today announced that Markus Renschler , M.D., Cyteir's president and chief executive officer, will present a scientific and business update at the 39th Annual J.P. Morgan Healthcare Conference on Monday,
Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer and Expands Senior Leadership Team
- Phase 1/2 study of first-in-class inhibitor of RAD51-mediated homologous recombination advancing to once-daily dosing - Secrist, Gengos and Englert join Cyteir leadership team, enhancing company's scientific, strategic business development, and drug development expertise
Cyteir Therapeutics Secures Additional $40.2 Million in Its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor
Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies for cancer, today announced the close of an additional $40.2 million in the company's Series B financing, for a total of $75.2 million in this financing
Cyteir Therapeutics snagged $29 million and a new chief executive officer as the company pushes forward to develop small-molecule inhibitors in the fight against cancer.
Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies for Cancer and Autoimmune Diseases
Financing proceeds will be used to advance RAD51 inhibitor toward the clinic and expand small-molecule synthetic lethality platform for oncology and autoimmune diseases.
Cyteir Therapeutics Announces Study Showing RAD51 Modulators Protect Diabetic Mice From Type 1 Diabetes (T1D)
Cyteir Therapeutics Presents Preclinical Data Validating RAD51-AID As A Novel Target For Cancer Treatment At AACR Annual Meeting
Cyteir Therapeutics Presents Preclinical Data On Use Of DNA Repair Modulators For Lymphoid Malignancies At American Society of Hematology Annual Meeting